Celera Appoints H. Robert Superko, M.D., as Vice President, Chief of Medical Affairs
FOR IMMEDIATE RELEASE
ALAMEDA, CA - April 30, 2009
Celera Corporation (NASDAQ:CRA) today announced the appointment of H. Robert Superko, M.D., to the newly created position of Vice President, Chief of Medical Affairs at Celera, effective June 1, 2009. In this role, Dr. Superko will provide medical leadership for Celera’s cardiovascular products and services through oversight of education programs and participation in relevant medical associations, professional societies and groups responsible for the establishment of guidelines regarding the adoption of new diagnostics. Dr. Superko will report to Kathy Ordoñez, Celera’s Chief Executive Officer.
Dr. Superko is a Fellow of the American College of Cardiology, the American Heart Association, the American College of Sports Medicine and the American Association of Cardiovascular and Pulmonary Rehabilitation. He is currently the Executive Director at the Center for Genomics and Human Health at St. Joseph’s Translational Research Institute in Atlanta, GA. He is also the Principal Investigator of the “Firefighter Heart Disease Prevention Program”, which is being funded by the Department of Homeland Security in Washington, DC. He is Clinical Professor in the College of Pharmacy and Health Sciences at Mercer University in Atlanta, GA, and has held various research and clinical positions at several institutions around the United States since completing his medical fellowship at the University of California at Davis in 1980. Dr. Superko was also a founder of Berkeley HeartLab in 1996.
“We are delighted that Robert has joined Celera to provide medical oversight to our cardiovascular programs, and to serve as the lead interface with the cardiovascular medical community,” said Ms. Ordoñez. “We believe Robert’s experience in helping facilitate clinical utilization of novel diagnostics will be important to our success as we seek to have tests, such Berkeley HeartLab’s KIF6 laboratory developed test, adopted broadly by the medical community.”
Dr. Superko sits on the editorial boards of several prestigious journals including the Journal of Cardiovascular Risk and Preventative Cardiology. He has published more than 120 peer-reviewed articles and chapters in the area of lipid metabolism, exercise physiology and cardiac rehabilitation, and he has written a number of books including, “Before the Heart Attacks” published in 2003. Dr. Superko currently sits on committees at the American Heart Association, the Trans Catheter Therapeutics Scientific Advisory Committee, American Heart Association Atherosclerotic Peripheral Vascular Disease Committee, and the Atlanta American Heart Association Board. He has appeared on many broadcast programs as an expert in the cardiovascular arena, most recently on a CNN health segment on cardiovascular disease.
Dr. Superko holds a Bachelor of Arts degree from the University of California, San Diego and a Doctor of Medicine degree from State University of New York, Stony Brook. After completing his internship, residency, and a fellowship at the University of California at Davis, Dr. Superko became a Certified Program Director at the American College of Sports Medicine for programs involving graded exercise for patients with cardiopulmonary disease.
“I am very excited to be joining Celera with its many compelling new discoveries in the cardiovascular disease pipeline,” said H. Robert Superko, M.D., “I think there is a terrific opportunity for new genetic tests, such as KIF6 and LPA, to have a profound impact on clinical care and drive the paradigm of personalized disease management to the benefit of physicians and their patients. The age of personalized medicine is here today and I am proud to participate in this medical advance as Vice President, Chief of Medical Affairs of Celera.”
Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “will,” “should,” “anticipate,” and “intend,” among others. These forward-looking statements are based on Celera’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Celera notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of our business include, but are not limited to, the risks and uncertainties that: (1) Celera is using novel and unproven methods to discover markers for the development of new diagnostic products, which may not be successful; (2) the diagnostic industry is very competitive, and new diagnostic products may not be accepted and adopted by the market; (3) demand for diagnostic products may be adversely affected if users of these products cannot receive adequate reimbursement for these products from third party payors such as private insurance companies and government insurance plans; (4) potential product liability or other claims against Celera as a result of the testing or use of its products; and (5) uncertainty of the availability to Celera of intellectual property protection, limitations on its ability to protect trade secrets, the risk to it of infringement claims, and the possibility that it may need to license intellectual property from third parties to avoid or settle such claims The foregoing list sets forth some, but not all, of the factors that could affect Celera's ability to achieve results described in any forward-looking statements. For additional information about the risks and uncertainties that Celera faces and a discussion of its financial statements and footnotes, see documents filed by Celera with the SEC, including its transition report on Form 10-KT and all subsequent periodic reports. All information in this press release is as of the date of the release, and Celera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Copyright© 2009. Celera Corporation. All Rights Reserved. Celera is a registered trademark of Celera Corporation or its subsidiaries in the U. S. and/or certain other countries.
David Speechly, Ph.D.
+1 (510) 749-1853
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.